%0 Journal Article
%T Apolipoprotein E Polymorphisms and Parkinson Disease With or Without Dementia: A Meta
%A Bing Zheng
%A Jianping Liu
%A Ruoyi Sun
%A Simin Yang
%A Xiaowei Ma
%J Journal of Geriatric Psychiatry and Neurology
%@ 1552-5708
%D 2019
%R 10.1177/0891988718813675
%X A large number of case¨Ccontrol studies have investigated the association of apolipoprotein E (APOE) polymorphisms with Parkinson disease (PD) and Parkinson disease dementia (PDD), with inconsistent results. This meta-analysis aimed to evaluate the relationship between APOE polymorphisms and PD/PDD risk. We searched for published studies in PubMed, Web of Science, WanFang Data (in Chinese), and CNKI (in Chinese) from inception to June 2017. Case¨Ccontrol studies reporting part or complete APOE genotype and allele frequency data were included. Pooled odds ratios (ORs) with 95% confidence intervals (95% CIs) were calculated using RevMan 5.3 software. A total of 39 studies involving 6453 cases with PD, with 461 cases with PDD, and 6855 controls were included in this meta-analysis. The results showed that the APOE ¦Å3 allele was a protective factor for PD (OR = 0.90, 95% CI: 0.81-0.99; P = .04), whereas no significant differences in PD risk among all cases compared to controls were found for APOE ¦Å2 and ¦Å4. In Asian subgroups, the APOE ¦Å4 allele was shown to be a risk factor for PD (OR = 1.22, 95% CI: 1.01-1.46; P = .04). Additionally, APOE polymorphisms were significantly associated with PDD risk in the entire case group (¦Å3: OR = 0.72, 95% CI: 0.58-0.89, P = .003; ¦Å4: OR = 1.46, 95% CI: 1.12-1.88, P = .004) and in Asian subgroups
%K apolipoprotein E
%K polymorphisms
%K Parkinson disease
%K Parkinson disease dementia
%K meta-analysis
%U https://journals.sagepub.com/doi/full/10.1177/0891988718813675